TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
TELA Bio (NASDAQ: TELA) approved inducement restricted stock unit grants covering 8,550 shares to three newly hired employees, with a grant date of February 18, 2026.
The RSUs vest in equal annual installments over four years and were issued under the Nasdaq Rule 5635(c)(4) inducement exception as part of each hire's employment compensation.
Positive
- None.
Negative
- None.
News Market Reaction – TELA
In the Feb 23 session, TELA gained 6.77%, reflecting a notable positive market reaction. Argus tracked a trough of -10.6% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 23 | Inducement grants | Neutral | -1.0% | RSU inducement grants for new hires under Nasdaq Rule 5635(c)(4). |
| Dec 12 | Inducement grants | Neutral | -1.7% | RSU inducement grants totaling 3,600 shares to three new employees. |
| Nov 19 | Conference participation | Neutral | -8.5% | Participation and webcast at a major healthcare investor conference. |
| Nov 17 | Inducement grants | Neutral | +14.1% | Inducement RSUs and stock option awards for newly hired employees. |
| Nov 13 | Equity offering | Neutral | -2.6% | Pricing of $13.0M registered direct offering of shares and pre-funded warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent similar inducement grant announcements have typically coincided with modestly negative to mixed next-day price moves.
Over the last few months, TELA Bio issued several routine updates, including multiple Nasdaq Rule 5635(c)(4) inducement equity grant announcements on Nov 17, 2025, Dec 12, 2025, and Jan 23, 2026, generally followed by modest price moves. A notable event was the $13.0 million underwritten registered direct offering on Nov 13, 2025, tied to a broader financing package. The current inducement RSU grants continue this pattern of incremental equity-based compensation disclosures.
Key Terms
nasdaq rule 5635(c)(4) regulatory
restricted stock units financial
inducement grant exception regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., Feb. 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 8,550 shares of its common stock to three newly-hired employees, with a grant date of February 18, 2026 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact Louisa Smith ir@telabio.com